Shandong Weigao Group Medical Polymer Company Limited (Weigao Group) disclosed a share buyback on 13 April 2026, acquiring 540,000 H-shares on the Hong Kong Stock Exchange at prices ranging from HKD 3.56 to HKD 3.66. The transaction, executed under its existing mandate, cost HKD 1.94 million, equivalent to a volume-weighted average price of HKD 3.60 per share.

The repurchase reduced the company’s issued share capital (excluding treasury shares) to 4.47 billion shares, representing a 0.0121% contraction from the 4.47 billion outstanding before the transaction. Concurrently, treasury shares rose to 50.75 million, leaving total issued shares unchanged at 4.52 billion.

Weigao Group’s current repurchase mandate, approved on 27 May 2025, authorises the buyback of up to 451.56 million shares. Following the latest transaction, 44.10 million shares—about 9.77 % of the authorised limit—have been repurchased under this mandate.

In accordance with Hong Kong Main Board Rule 10.06, the company is subject to a 30-day moratorium on issuing new shares or disposing of treasury shares, extending through 14 May 2026. The board confirmed that all repurchase activities complied with applicable listing rules and regulatory requirements.